Mitophagy in Alzheimer's disease: Molecular defects and therapeutic approaches.

Animals; Humans; Alzheimer Disease/metabolism; Mitophagy/physiology; Autophagy/genetics; Mitochondria/metabolism; Disease Models, Animal; Amyloid beta-Peptides/metabolism

Abstract :

[en] Mitochondrial dysfunctions are central players in Alzheimer's disease (AD). In addition, impairments in mitophagy, the process of selective mitochondrial degradation by autophagy leading to a gradual accumulation of defective mitochondria, have also been reported to occur in AD. We provide an updated overview of the recent discoveries and advancements on mitophagic molecular dysfunctions in AD-derived fluids and cells as well as in AD brains. We discuss studies using AD cellular and animal models that have unraveled the contribution of relevant AD-related proteins (Tau, Aβ, APP-derived fragments and APOE) in mitophagy failure. In accordance with the important role of impaired mitophagy in AD, we report on various therapeutic strategies aiming at stimulating mitophagy in AD and we summarize the benefits of these potential therapeutic strategies in human clinical trials.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

MARY, Arnaud ; Université Côte d'Azur, INSERM, CNRS, IPMC, France, Laboratory of excellence DistALZ, 660 route des Lucioles,6560, Sophia-Antipolis, Valbonne, France.

Eysert, Fanny

Checler, Frédéric

Chami, Mounia

External co-authors :

yes

Language :

English

Title :

Mitophagy in Alzheimer's disease: Molecular defects and therapeutic approaches.

Publication date :

2023

Journal title :

Molecular Psychiatry

ISSN :

1476-5578

Publisher :

Nature Publishing Group, United Kingdom

Volume :

Issue :

Pages :

202-216

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBilu :

since 12 September 2023

Statistics

Number of views

27 (8 by Unilu)

Number of downloads

5 (2 by Unilu)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

WoS citations^™

Bibliography

De Strooper B, Karran E. The cellular phase of Alzheimer’s disease. Cell. 2016;164:603–15.
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nat Rev Dis Prim. 2015;1:15056.
Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol Psychiatry. 2021;26:5481–503.
Nhan HS, Chiang K, Koo EH. The multifaceted nature of amyloid precursor protein and its proteolytic fragments: Friends and foes. Acta Neuropathol. 2015;129:1–19.
Ashrafi G, Schlehe JS, LaVoie MJ, Schwarz TL. Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. J Cell Biol. 2014;206:655–70.
Lin M-Y, Cheng X-T, Tammineni P, Xie Y, Zhou B, Cai Q, et al. Releasing syntaphilin removes stressed mitochondria from axons independent of mitophagy under pathophysiological conditions. Neuron 2017;94:595–610.e6.
Kobro-Flatmoen A, Lagartos-Donate MJ, Aman Y, Edison P, Witter MP, Fang EF. Re-emphasizing early Alzheimer’s disease pathology starting in select entorhinal neurons, with a special focus on mitophagy. Ageing Res Rev. 2021;67:101307.
Armand-Ugon M, Ansoleaga B, Berjaoui S, Ferrer I. Reduced Mitochondrial Activity is Early and Steady in the Entorhinal Cortex but it is Mainly Unmodified in the Frontal Cortex in Alzheimer’s Disease. Curr Alzheimer Res. 2017;14:1327–34.
Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, et al. Mitophagy and Alzheimer’s Disease: Cellular and molecular mechanisms. Trends Neurosci. 2017;40:151–66.
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer’s disease. The. J Neurosci: Off J Soc Neurosci. 2001;21:3017–23.
Hu Y, Li X-C, Wang Z-H, Luo Y, Zhang X, Liu X-P, et al. Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin. Oncotarget 2016;7:17356–68.
Martín-Maestro P, Gargini R, Perry G, Avila J, García-Escudero V. PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer’s disease. Hum Mol Genet. 2016;25:792–806.
Du F, Yu Q, Yan S, Hu G, Lue L-F, Walker DG, et al. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer’s disease. Brain: A J Neurol. 2017;140:3233–51.
Martín-Maestro P, Gargini R, García E, Perry G, Avila J, García-Escudero V. Slower dynamics and aged mitochondria in sporadic Alzheimer’s Disease. Oxid Med Cell Longev. 2017;2017:1–14.
Sohn HY, Kim SI, Park JY, Park SH, Koh YH, Kim J, et al. ApoE4 attenuates autophagy via FoxO3a repression in the brain. Sci Rep. 2021;11:17604.
Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat Neurosci. 2019;22:401–12.
Ye X, Sun X, Starovoytov V, Cai Q. Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer’s disease patient brains. Hum Mol Genet. 2015;24:2938–51.
Vaillant-Beuchot L, Mary A, Pardossi-Piquard R, Bourgeois A, Lauritzen I, Eysert F, et al. Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer’s disease models and human brains. Acta Neuropathologica. 2021;141:39–65.
Wang Z-T, Lu M-H, Zhang Y, Ji W-L, Lei L, Wang W, et al. Disrupted-in-schizophrenia-1 protects synaptic plasticity in a transgenic mouse model of Alzheimer’s disease as a mitophagy receptor. Aging Cell. 2019;18:e12860.
Drabik K, Malińska D, Piecyk K, Dębska-Vielhaber G, Vielhaber S, Duszyński J, et al. Effect of chronic stress present in fibroblasts derived from patients with a sporadic form of AD on mitochondrial function and mitochondrial turnover. Antioxidants (Basel, Switzerland). 2021;10:938.
Martín-Maestro P, Gargini R, A. Sproul A, García E, Antón LC, Noggle S, et al. Mitophagy failure in fibroblasts and iPSC-derived neurons of Alzheimer’s Disease-associated presenilin 1 Mutation. Front Mol Neurosci. 2017;10:291.
Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010;141:1146–58.
Coffey EE, Beckel JM, Laties AM, Mitchell CH. Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer’s disease-linked presenilin 1 A246E mutation can be reversed with cAMP. Neuroscience 2014;263:111–24.
Martín-Maestro P, Sproul A, Martinez H, Paquet D, Gerges M, Noggle S, et al. Autophagy Induction by Bexarotene Promotes Mitophagy in Presenilin 1 Familial Alzheimer’s Disease iPSC-Derived Neural Stem Cells. Mol Neurobiol. 2019;56:8220–36.
Du F, Yu Q, Yan SS. PINK1 Activation Attenuates Impaired Neuronal-Like Differentiation and Synaptogenesis and Mitochondrial Dysfunction in Alzheimer’s Disease Trans-Mitochondrial Cybrid Cells. J Alzheimers Dis. 2021;81:1749–61.
Castellazzi M, Patergnani S, Donadio M, Giorgi C, Bonora M, Bosi C, et al. Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer’s disease and mild cognitive impairment. Scientific Rep. 2019;9:20009.
Pakpian N, Phopin K, Kitidee K, Govitrapong P, Wongchitrat P. Alterations in mitochondrial dynamic-related genes in the peripheral blood of Alzheimer’s disease patients. Curr Alzheimer Res. 2020;17:616–25.
Watzlawik JO, Hou X, Fricova D, Ramnarine C, Barodia SK, Gendron TF, et al. Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples. Autophagy. 2021;17:2613–28.
Amadoro G, Corsetti V, Florenzano F, Atlante A, Ciotti MT, Mongiardi MP, et al. AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons. Neurobiol Dis. 2014;62:489–507.
Corsetti V, Florenzano F, Atlante A, Bobba A, Ciotti MT, Natale F, et al. NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer’s disease. Hum Mol Genet. 2015;24:3058–81.
Cummins N, Tweedie A, Zuryn S, Bertran-Gonzalez J, Götz J. Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria. The EMBO J. 2019;38:e99360.
Guha S, Fischer S, Johnson GVW, Nehrke K. Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model. Mol Neurodegeneration. 2020;15:65.
Wang N, Wang H, Li L, Li Y, Zhang R. β-Asarone inhibits Amyloid-β by promoting autophagy in a cell model of Alzheimer’s Disease. Front Pharmacol. 2020;10:1529.
Wang H, Jiang T, Li W, Gao N, Zhang T. Resveratrol attenuates oxidative damage through activating mitophagy in an in vitro model of Alzheimer’s disease. Toxicol Lett. 2018;282:100–8.
Zhang L, Fang Y, Zhao X, Zheng Y, Ma Y, Li S, et al. miR-204 silencing reduces mitochondrial autophagy and ROS production in a murine AD model via the TRPML1-activated STAT3 pathway. Mol Ther Nucleic Acids. 2021;24:822–31.
Wang H, Zhang T, Ge X, Chen J, Zhao Y, Fu J. Parkin overexpression attenuates Aβ-induced mitochondrial dysfunction in HEK293 cells by restoring impaired mitophagy. Life Sci. 2020;244:117322.
Han Y, Wang N, Kang J, Fang Y. β-Asarone improves learning and memory in Aβ1-42-induced Alzheimer’s disease rats by regulating PINK1-Parkin-mediated mitophagy. Metab Brain Dis. 2020;35:1109–17
Tammineni P, Ye X, Feng T, Aikal D, Cai Q. Impaired retrograde transport of axonal autophagosomes contributes to autophagic stress in Alzheimer’s disease neurons. eLife. 2017;6:e21776.
Guglielmotto M, Monteleone D, Piras A, Valsecchi V, Tropiano M, Ariano S, et al. Aβ1-42 monomers or oligomers have different effects on autophagy and apoptosis. Autophagy 2014;10:1827–43.
Pardossi-Piquard R, Checler F. The physiology of the β-amyloid precursor protein intracellular domain AICD. J Neurochem. 2012;120(Suppl 1):109–24.
Goiran T, Duplan E, Chami M, Bourgeois A, El Manaa W, Rouland L, et al. β-Amyloid precursor protein intracellular domain controls mitochondrial function by modulating phosphatase and Tensin Homolog-Induced Kinase 1 Transcription in Cells and in Alzheimer Mice Models. Biol Psychiatry. 2018;83:416–27.
Duplan E, Sevalle J, Viotti J, Goiran T, Bauer C, Renbaum P, et al. Parkin differently regulates presenilin-1 and presenilin-2 functions by direct control of their promoter transcription. J Mol Cell Biol. 2013;5:132–42.
Checler F, Afram E, Pardossi-Piquard R, Lauritzen I. Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99? J Biol Chem. 2021;296:100489.
Pulina MV, Hopkins M, Haroutunian V, Greengard P, Bustos V. C99 selectively accumulates in vulnerable neurons in Alzheimer’s disease. Alzheimer’s Dement: J Alzheimer’s Assoc. 2020;16:273–82.
Lauritzen I, Pardossi-Piquard R, Bourgeois A, Pagnotta S, Biferi M-G, Barkats M, et al. Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology. Acta Neuropathologica. 2016;132:257–76.
Lauritzen I, Pardossi-Piquard R, Bauer C, Brigham E, Abraham JD, Ranaldi S, et al. The beta-secretase-derived C-terminal fragment of betaAPP, C99, but not Abeta, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J Neurosci. 2012;32:16243–1655a.
Bourgeois A, Lauritzen I, Lorivel T, Bauer C, Checler F, Pardossi-Piquard R. Intraneuronal accumulation of C99 contributes to synaptic alterations, apathy-like behavior, and spatial learning deficits in 3×TgAD and 2×TgAD mice. Neurobiol Aging. 2018;71:21–31.
Hung COY, Livesey FJ. Altered γ-Secretase processing of APP disrupts lysosome and autophagosome function in monogenic Alzheimer’s Disease. Cell Rep. 2018;25:3647–60.e2.
Kwart D, Gregg A, Scheckel C, Murphy EA, Paquet D, Duffield M, et al. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP β-CTFs, Not Aβ. Neuron 2019;104:256–70.e5.
Del Prete D, Suski JM, Oulès B, Debayle D, Gay AS, Lacas-Gervais S, et al. Localization and processing of the Amyloid-β protein precursor in mitochondria-associated membranes. J Alzheimer’s Dis. 2017;55:1549–70.
Pera M, Larrea D, Guardia‐Laguarta C, Montesinos J, Velasco KR, Agrawal RR, et al. Increased localization of APP‐C99 in mitochondria‐associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. The. EMBO J. 2017;36:3356–71.
Montesinos J, Pera M, Larrea D, Guardia-Laguarta C, Agrawal RR, Velasco KR, et al. The Alzheimer’s disease-associated C99 fragment of APP regulates cellular cholesterol trafficking. Embo J. 2020;39:e103791.
Yang M, Li C, Yang S, Xiao Y, Xiong X, Chen W, et al. Mitochondria-associated ER Membranes - The origin site of autophagy. Front Cell Dev Biol. 2020;8:595.
Gelmetti V, De Rosa P, Torosantucci L, Marini ES, Romagnoli A, Di Rienzo M, et al. PINK1 and BECN1 relocalize at mitochondria-associated membranes during mitophagy and promote ER-mitochondria tethering and autophagosome formation. Autophagy 2017;13:654–69.
McLelland GL, Goiran T, Yi W, Dorval G, Chen CX, Lauinger ND, et al. Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy. Elife. 2018;7:e32866.
Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, de Groof AJ, Madra M, et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 2012;31:4106–23.
Lee SE, Kwon D, Shin N, Kong D, Kim NG, Kim HY, et al. Accumulation of APP-CTF induces mitophagy dysfunction in the iNSCs model of Alzheimer’s disease. Cell Death Discov. 2022;8:1.
Parcon PA, Balasubramaniam M, Ayyadevara S, Jones RA, Liu L, Shmookler Reis RJ, et al. Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs. Alzheimer’s Dement: J Alzheimer’s Assoc. 2018;14:230–42.
Lefterov I, Wolfe CM, Fitz NF, Nam KN, Letronne F, Biedrzycki RJ, et al. APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain. Alzheimers Res Ther. 2019;11:113.
Simonovitch S, Schmukler E, Masliah E, Pinkas-Kramarski R, Michaelson DM. The Effects of APOE4 on Mitochondrial Dynamics and Proteins in vivo. J Alzheimer’s Dis: JAD. 2019;70:861–75.
Schmukler E, Solomon S, Simonovitch S, Goldshmit Y, Wolfson E, Michaelson DM, et al. Altered mitochondrial dynamics and function in APOE4-expressing astrocytes. Cell Death Dis. 2020;11:578.
Lee SI, Jeong W, Lim H, Cho S, Lee H, Jang Y, et al. APOE4-carrying human astrocytes oversupply cholesterol to promote neuronal lipid raft expansion and Aβ generation. Stem cell Rep. 2021;16:2128–37.
Roca-Agujetas V, Barbero-Camps E, de Dios C, Podlesniy P, Abadin X, Morales A, et al. Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease. Mol Neurodegener. 2021;16:15.
Han S, Jeong YY, Sheshadri P, Su X, Cai Q. Mitophagy regulates integrity of mitochondria at synapses and is critical for synaptic maintenance. EMBO reports. 2020;21:e49801.
Zheng YR, Zhang XN, Chen Z. Mitochondrial transport serves as a mitochondrial quality control strategy in axons: Implications for central nervous system disorders. CNS Neurosci Ther. 2019;25:876–86.
Kam MK, Lee DG, Kim B, Huh J-W, Lee HJ, Park Y-H, et al. Amyloid-beta oligomers induce Parkin-mediated mitophagy by reducing Miro1. Biochem J. 2020;477:4581–97.
Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-Félix AA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. 2016;22:879–88.
Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019;1:595–603.
Aman Y, Frank J, Lautrup SH, Matysek A, Niu Z, Yang G, et al. The NAD(+)-mitophagy axis in healthy longevity and in artificial intelligence-based clinical applications. Mechanisms ageing Dev. 2020;185:111194.
Fang EF. Mitophagy and NAD(+) inhibit Alzheimer disease. Autophagy 2019;15:1112–4.
Sorrentino V, Romani M, Mouchiroud L, Beck JS, Zhang H, D’Amico D, et al. Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity. Nature 2017;552:187–93.
Phelan MJ. Phase II Clinical Trial of Nicotinamide for the Treatment of Mild to Moderate Alzheimer’s Disease. J Geriatric Med Gerontol. 2017;3:021.
Tang Q, Zheng G, Feng Z, Chen Y, Lou Y, Wang C, et al. Trehalose ameliorates oxidative stress-mediated mitochondrial dysfunction and ER stress via selective autophagy stimulation and autophagic flux restoration in osteoarthritis development. Cell Death Dis 2017;8:e3081-e.
Zhu L, Yuan Y, Yuan L, Li L, Liu F, Liu J, et al. Activation of TFEB-mediated autophagy by trehalose attenuates mitochondrial dysfunction in cisplatin-induced acute kidney injury. Theranostics 2020;10:5829–44.
Khalifeh M, Read MI, Barreto GE, Sahebkar A. Trehalose against Alzheimer’s Disease: Insights into a potential therapy. BioEssays 2020;42:1900195.
Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR. Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci. 2014;6:218.
Porquet D, Griñán-Ferré C, Ferrer I, Camins A, Sanfeliu C, Del Valle J, et al. Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer’s disease. J Alzheimer’s Dis: JAD. 2014;42:1209–20.
Chimento A, De Amicis F, Sirianni R, Sinicropi MS, Puoci F, Casaburi I, et al. Progress to improve oral bioavailability and beneficial effects of resveratrol. Int J Mol Sci. 2019;20:1381.
Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (N. Y, NY). 2012;335:1503–6.
Pierrot N, Lhommel R, Quenon L, Hanseeuw B, Dricot L, Sindic C, et al. Targretin improves cognitive and biological markers in a patient with Alzheimer’s Disease. J Alzheimer’s Dis: JAD. 2016;49:271–6.
Zhang L, Chen J. Biological effects of Tetrahydroxystilbene Glucoside: An active component of a rhizome extracted from polygonum multiflorum. Oxidative Med Cellular Longevity. 2018;2018:3641960.
Gao Y, Li J, Li J, Hu C, Zhang L, Yan J, et al. Tetrahydroxy stilbene glycoside alleviated inflammatory damage by mitophagy via AMPK related PINK1/Parkin signaling pathway. Biochemical Pharmacol. 2020;177:113997.
Deng M, Huang L, Zhong X. β-asarone modulates Beclin-1, LC3 and p62 expression to attenuate Aβ40 and Aβ42 levels in APP/PS1 transgenic mice with Alzheimer’s disease. Mol Med Rep. 2020;21:2095–102.
Sun C, Qiu X, Wang Y, Liu J, Li Q, Jiang H, et al. Long-term oral melatonin alleviates memory deficits, reduces amyloid-β deposition associated with downregulation of BACE1 and mitophagy in APP/PS1 transgenic mice. Neurosci Lett. 2020;735:135192.
Morselli E, Mariño G, Bennetzen MV, Eisenberg T, Megalou E, Schroeder S, et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol. 2011;192:615–29.
Eisenberg T, Knauer H, Schauer A, Büttner S, Ruckenstuhl C, Carmona-Gutierrez D, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. 2009;11:1305–14.
Qi Y, Qiu Q, Gu X, Tian Y, Zhang Y. ATM mediates spermidine-induced mitophagy via PINK1 and Parkin regulation in human fibroblasts. Sci Rep. 2016;6:24700.
Yang X, Zhang M, Dai Y, Sun Y, Aman Y, Xu Y, et al. Spermidine inhibits neurodegeneration and delays aging via the PINK1-PDR1-dependent mitophagy pathway in C. elegans. Aging 2020;12:16852–66.
Wirth M, Benson G, Schwarz C, Köbe T, Grittner U, Schmitz D, et al. The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial. Cortex 2018;109:181–8.
Cen X, Chen Y, Xu X, Wu R, He F, Zhao Q, et al. Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an Alzheimer’s disease mouse model. Nat Commun. 2020;11:5731.
Xie C, Zhuang XX, Niu Z, Ai R, Lautrup S, Zheng S, et al. Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nat Biomed Eng. 2022;6:76–93.
Moradi-Afrapoli F, Oufir M, Walter FR, Deli MA, Smiesko M, Zabela V, et al. Validation of UHPLC-MS/MS methods for the determination of kaempferol and its metabolite 4-hydroxyphenyl acetic acid, and application to in vitro blood-brain barrier and intestinal drug permeability studies. J Pharm Biomed Anal. 2016;128:264–74.
Holland TM, Agarwal P, Wang Y, Leurgans SE, Bennett DA, Booth SL, et al. Dietary flavonols and risk of Alzheimer dementia. Neurology 2020;94:e1749–e56.
Song YM, Lee WK, Lee YH, Kang ES, Cha BS, Lee BW. Metformin restores parkin-mediated mitophagy, Suppressed by Cytosolic p53. Int J Mol Sci. 2016;17:122.
Bhansali S, Bhansali A, Dhawan V. Metformin promotes mitophagy in mononuclear cells: A potential in vitro model for unraveling metformin’s mechanism of action. Ann N Y Acad Sci. 2020;1463:23–36.
Bharath LP, Agrawal M, McCambridge G, Nicholas DA, Hasturk H, Liu J, et al. Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation. Cell Metab. 2020;32:44–55 e6.
Chen JL, Luo C, Pu D, Zhang GQ, Zhao YX, Sun Y, et al. Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance. Exp Neurol. 2019;311:44–56.
Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA. 2010;107:21830–5.
Ou Z, Kong X, Sun X, He X, Zhang L, Gong Z, et al. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice. Brain Behav Immun. 2018;69:351–63.
Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the Insulin sensitizer metformin in Alzheimer Disease: Pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis Assoc Disord. 2017;31:107–13.
Lee HJ, Seo HI, Cha HY, Yang YJ, Kwon SH, Yang SJ. Diabetes and Alzheimer’s Disease: Mechanisms and nutritional aspects. Clin Nutr Res. 2018;7:229–40.
Chin-Hsiao T. Metformin and the risk of dementia in type 2 diabetes patients. Aging Dis. 2019;10:37–48.
Campbell JM, Stephenson MD, de Courten B, Chapman I, Bellman SM, Aromataris E. Metformin use associated with reduced risk of dementia in patients with diabetes: A systematic review and meta-analysis. J Alzheimers Dis. 2018;65:1225–36.
McGurran H, Glenn JM, Madero EN, Bott NT. Prevention and treatment of Alzheimer’s Disease: Biological mechanisms of exercise. J Alzheimer’s Dis: JAD. 2019;69:311–38.
Revilla S, Suñol C, García-Mesa Y, Giménez-Llort L, Sanfeliu C, Cristòfol R. Physical exercise improves synaptic dysfunction and recovers the loss of survival factors in 3xTg-AD mouse brain. Neuropharmacology 2014;81:55–63.
Koo J-H, Kang E-B, Oh Y-S, Yang D-S, Cho J-Y. Treadmill exercise decreases amyloid-β burden possibly via activation of SIRT-1 signaling in a mouse model of Alzheimer’s disease. Exp Neurol. 2017;288:142–52.
Zhao N, Xia J, Xu B. Physical exercise may exert its therapeutic influence on Alzheimer’s disease through the reversal of mitochondrial dysfunction via SIRT1-FOXO1/3-PINK1-Parkin-mediated mitophagy. J Sport Health Sci. 2021;10:1–3.
Zhao N, Yan Q-W, Xia J, Zhang X-L, Li B-X, Yin L-Y, et al. Treadmill exercise attenuates aβ-induced mitochondrial dysfunction and enhances mitophagy activity in APP/PS1 transgenic mice. Neurochem Res. 2020;45:1202–14.
Mehrabani S, Bagherniya M, Askari G, Read MI, Sahebkar A. The effect of fasting or calorie restriction on mitophagy induction: A literature review. J Cachexia Sarcopenia Muscle. 2020;11:1447–58.
Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem. 2006;281:21745–54.
Schafer MJ, Alldred MJ, Lee SH, Calhoun ME, Petkova E, Mathews PM, et al. Reduction of beta-amyloid and gamma-secretase by calorie restriction in female Tg2576 mice. Neurobiol Aging. 2015;36:1293–302.
Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM, et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2007;26:212–20.
Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF. Preclinical and clinical evidence of NAD(+) precursors in health, disease, and ageing. Mechanisms Ageing Dev. 2021;199:111567.
Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s Disease. J Alzheimer’s Dis: JAD. 2018;62:1403–16.